INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 45h ago
HOUSE PTR5h ago
SEC 13F5h ago
ROBINHOOD CHAIN5h ago
SEC FORM 4/Open-market purchaseVerified data

Equels Thomas K bought AIM

Director, CEO & President · AIM ImmunoTech Inc. · Common Stock

Side
BUY
Value
$5,068
Shares
31.7K
Price
$0.16
Executed
Oct 23, 2026
Disclosed
Oct 26, 2026
Disclosure timeline3 days from execution to publication · legal deadline 2 business days
Oct 23 executedOct 26, 2026 disclosed

AIM · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
33/ 100 · ELEVATED
Methodology →
  • Transaction type+20 / 20

    Open-market purchase

  • Relative size+9 / 25

    $5K reported value · 20.0% of prior position

  • Filing timing0 / 15

    Disclosed 1 business day after execution (deadline: 2)

  • Historical behavior+4 / 15

    1 prior trade recorded in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · AIM

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    37
    EK
    Equels Thomas KDirector, CEO & President
    AIMAIM ImmunoTech Inc.
    Open-market purchase
    		BUY$5,094
    31.3K sh
    		Oct 22, 2026Oct 23, 2026
    traded Oct 22, 2026
    		+1dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001493152-26-048460
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Oct 23, 2026
    Published
    Oct 26, 2026
    Ingested by INSIDER
    Nov 5, 02:09 UTC
    Last re-read
    Nov 5, 02:09 UTC

    Extracted facts

    Filer
    Equels Thomas K
    Role
    Director, CEO & President
    Transaction
    Open-market purchaseAs filed: “P”
    Asset
    AIM ImmunoTech Inc.
    Ticker
    AIM
    Shares
    31.7K
    Price per share
    $0.16
    Value
    $5,068
    Execution date (reported)
    Oct 23, 2026
    Owned after transaction
    189.7K shares
    Days from execution to publication
    3

    Calculation

    Value = shares × reported price per share

    • Shares: 31.7K
    • Price: $0.16

    = $5,068

    What this establishes

    Equels Thomas K filed this Form 4 reporting a open-market purchase of AIM on Oct 23, 2026. It became public on Oct 26, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director, CEO & President
    Equels Thomas Kcik:0001450324
    Issuer
    AIM ImmunoTech Inc.cik:0000946644

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.